Prospecto: information for the user
Levodopa/Carbidopa/Entacapona Abdi 100 mg/25 mg/200 mg film-coated tablets EFG
Levodopa/carbidopa/entacapone
5.Storage of Levodopa/Carbidopa/Entacapona Abdi
6.Contents of the package and additional information
This medication contains three active principles (levodopa, carbidopa and entacapone) in a coated tablet. This medication is used to treat Parkinson's disease.
Parkinson's disease is due to low concentration in the brain of a substance called dopamine. Levodopa increases the amount of dopamine and thereby reduces the symptoms of Parkinson's disease. Carbidopa and entacapone improve the antiparkinsonian effects of levodopa.
Consult your doctor or pharmacist before starting to take Levodopa/Carbidopa/Entacapona Abdi if you have or have had:any of the following:
Consult your doctor if you are taking:
Consult your doctor if during treatment with Levodopa/Carbidopa/Entacapona Abdi:
Inform your doctor if you, or your family/caregiver, notice that you are developing symptoms similar to addiction, which lead to a desire for large doses of Stalevo and other medications used to treat Parkinson's disease.
Inform your doctor if you, or your family/caregiver, notice that you are developing symptoms similar to addiction, which lead to a desire for large doses of this medication and other medications used to treat Parkinson's disease.
Inform your doctor if you or your family/caregiver notice that you are developing desires or a propensity to behave in an unusual way in you or that you cannot resist the impulse, determination, or temptation to engage in certain activities that may harm you or others. These behaviors are known as impulse control disorders and may include excessive gaming, eating, or spending, and an abnormally elevated or concerning sexual impulse.Your doctor may need to review your treatment.
During prolonged treatment with this medication, your doctor may perform regular analytical tests.
If you need to undergo surgery, inform your doctor that you are taking this medication.
This medication is not recommended for the treatment of extrapyramidal symptoms (e.g., involuntary movements, agitation, muscle rigidity, and muscle contractions) caused by other medications.
The experience of using this medication in patients under 18 years old is limited. Therefore, its administration in children or adolescents is not recommended.
Inform your doctor or pharmacist if you are taking, have taken recently, or may need to take any other medication.
Do not take this medication if you are taking certain medications for depression (combinations of MAO-A and MAO-B inhibitors, or non-selective MAO inhibitors).
This medication may increase the effect, and also the adverse effects, of certain medications. These include:
Certain medications may reduce the effects of this medication. These medications are:
This medication may make it difficult for the body to absorb iron at the digestive level. Therefore, do not take this medication at the same time as taking iron supplements. If you take any of them, wait at least 2 or 3 hours before taking the other.
Consult your doctor if you think this occurs in your case.
If you are pregnant or breastfeeding, or if you think you may be pregnant, consult your doctor or pharmacist before using this medication.
Do not breastfeed your child during treatment with this medication.
This medication may lower your blood pressure, which may cause dizziness or fainting. Therefore, be especially careful when handling tools or machinery.
If you feel very tired or notice that you fall asleep suddenly, wait until you feel fully awake again before driving or doing anything else that requires you to be alert. If not, you may put yourself and others at risk of a serious or even fatal accident.
Follow exactly the administration instructions for this medication as indicated by your doctor or pharmacist. In case of doubt, consult your doctor or pharmacist again.
Adults and the elderly
Speak with your doctor or pharmacist if you believe the effect of this medication is too intense or too weak, or if you experience possible side effects.
If you have accidentally taken more tablets of this medication than you should, speak immediately with your doctor or pharmacist. In case of overdose, you may feel dazed or agitated, that the heart rate is slower or faster than normal, or that the color of your skin, tongue, eyes, or urine has changed.
In case of overdose or accidental ingestion, consult your doctor or pharmacist or call the Toxicological Information Service, phone: 91 562 04 20, indicating the medication and the amount ingested.
Do not take a double dose to compensate for the missed doses.
If more than 1 hour remains until the next dose:
Take a tablet as soon as you remember, and the next one at the regular time.
If less than 1 hour remains until the next dose:
Take a tablet as soon as you remember, wait 1 hour, and then take another tablet. Continue as usual.
Always allow 1 hour to pass between tablets of this medication to avoid possible side effects.
Do not stop taking this medication unless your doctor tells you to. In that case, your doctor may need to adjust the dose of other Parkinson's medications, especially levodopa, to ensure sufficient control of your symptoms. If you stop taking this medication and other Parkinson's medications abruptly, you may experience unwanted side effects.
If you have any other questions about the use of this medication, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everyone will experience them. Many can be relieved by adjusting the dose.
If you experience any of these symptoms during treatment with this medicine,contact your doctor immediately:
Very common (may affect more than 1 in 10 people):
Common (may affect up to 1 in 10 people):
Rare (may affect up to 1 in 100 people):
Frequency not known (cannot be estimated from available data):
Desire for large doses of this medicine exceeding those required to control motor symptoms, known as dopamine dysregulation syndrome. Some patients experience severe abnormal involuntary movements (dyskinesias), mood changes, or other adverse effects after taking large doses of this medicine.
The following adverse effects have also been reported:
You may experience the following adverse effects:
Inform your doctor if you experience any of these behaviors: they will discuss how to manage or reduce these symptoms.
If you experience any type of adverse effect, consult your doctor or pharmacist, even if it is a possible adverse effect not listed in this prospectus. You can also report them directly through the Spanish System for Pharmacovigilance of Medicines for Human Use www.noticaRAM.es. By reporting adverse effects, you can contribute to providing more information on the safety of this medicine.
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date that appears on the box after CAD. The expiration date is the last day of the month indicated.
Store at a temperature below 86°F (30°C).
Store in the original packaging and keep the bottle tightly closed to protect it from moisture.
Medications should not be disposed of through drains or trash. Dispose of the containers and medications you no longer need at the SIGRE collection point of the pharmacy. If in doubt, ask your pharmacist how to dispose of the containers and medications you no longer need. By doing so, you will help protect the environment.
Hydroxypropylmethylcellulose type 2910
Titanium dioxide E 171
Glycerol E 422
Iron oxide red E 172
Iron oxide yellow E 172
Magnesium stearate E 470b
Polysorbate 80 E 433
Hydroxypropylcellulose E 463
Biconvex, oval-shaped tablets, film-coated, reddish-brown in color with "100" engraved on one face of the tablet and the other face flat. Size: 16.6 mm x 7.8 mm
There are three different package sizes (30, 100, or 175 film-coated tablets) of this medication. The packages consist of HDPE bottles with induction-sealed aluminum caps and a silica gel-filled container as a loose component in the bottle. The HDPE bottle is packed in an external cardboard box.
Only some package sizes may be commercially available.
Marketing Authorization Holder
Abdi Farma GmbH
Donnersbergstraße 4,
64646 Heppenheim
Germany
Responsible for manufacturing
Pharmadox Healthcare Limited
Kkw46 Kordin Industrial Park,
Paola, PLA 3000
Malta
For more information about this medication, please contact the local representative of the marketing authorization holder:
Spain:
Xentenel Pharma Europe, S.L.
Camí Can Camps, 17
Vallsolana Garden Business Park
08174 Sant Cugat del Vallés (Barcelona)
Spain
Other sources of information
Detailed and updated information about this medication is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS)http://www.aemps.gob.es/
Есть вопросы по этому лекарству или вашим симптомам? Свяжитесь с лицензированным врачом для получения помощи и персонализированного ухода.